genedrive, a UK-based diagnostics company and developer of rapid point-of-care genetic tests, has welcomed the publication of the NHS Implementation Guide for CYP2C19 genotype testing to support clopidogrel prescribing decisions following ischaemic stroke (IS) and transient ischaemic attack (TIA).
The guidance provides practical direction for NHS stroke and TIA services considering rapid point-of-care testing and recognises the challenges of short inpatient stays and delays associated with laboratory testing. It builds on national pilot data presented at the recent UK Stroke Forum, conducted across four geographically diverse NHS stroke units.
Results showed a higher prevalence of clopidogrel non-responders identified with rapid testing (33%) compared with laboratory testing (29%) and that all patients tested at the bedside had results before discharge, enabling actionable prescribing decisions. The data estimated around 4,200 additional stroke patients per year could benefit from alternative therapy with broader variant coverage and that rapid CYP2C19 testing was feasible, scalable and effective in real-world acute care.
As rapid point-of-care CYP2C19 testing requires local funding decisions at Trust and Integrated Care Board (ICB) level, genedrive supports stroke teams with evidence-based discussions and implementation planning.
Organisations considering rapid CYP2C19 testing or preparing for local ICB discussions are encouraged to engage with genedrive to explore how the NHS guidance and pilot evidence can support local adoption.
For more information, please contact us at [email protected]
